Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib with Idarubicin/Cytarabine in Relapsed/Refractory AML
NCT02635074Phase 1Terminated
- Start
- Nov 2016
- Primary completion
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ibrutinib in acute myeloid leukemia (AML). Primary endpoint: Safety and Recommended Phase 2 Dose. Started Nov 2016; status: terminated.
02
Drugs
ibrutinib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02635074.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02635074.